Shares of Synthetic Biologics Inc (NYSEMKT:SYN) have been assigned a consensus rating of “Buy” from the eight brokerages that are currently covering the company, MarketBeat reports. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating and five have assigned a buy rating to the company. The average 12 month target price among brokerages that have issued a report on the stock in the last year is $4.46.

A number of equities analysts have issued reports on the company. William Blair reiterated an “outperform” rating and set a $5.00 target price on shares of Synthetic Biologics in a report on Monday, May 22nd. Zacks Investment Research upgraded Synthetic Biologics from a “hold” rating to a “buy” rating and set a $0.50 target price for the company in a report on Wednesday, May 10th. Finally, ValuEngine cut Synthetic Biologics from a “sell” rating to a “strong sell” rating in a report on Friday, June 2nd.

Synthetic Biologics (NYSEMKT SYN) traded down 4.974% during mid-day trading on Tuesday, reaching $0.661. The company had a trading volume of 1,713,533 shares. The stock’s market cap is $80.57 million. The firm’s 50-day moving average price is $0.57 and its 200-day moving average price is $0.71. Synthetic Biologics has a 12 month low of $0.41 and a 12 month high of $1.94.

Synthetic Biologics (NYSEMKT:SYN) last released its earnings results on Thursday, May 4th. The company reported ($0.02) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.07) by $0.05. Equities research analysts forecast that Synthetic Biologics will post ($0.25) EPS for the current fiscal year.

ILLEGAL ACTIVITY NOTICE: This report was first posted by Financial Market News and is owned by of Financial Market News. If you are accessing this report on another website, it was stolen and reposted in violation of U.S. and international trademark & copyright legislation. The legal version of this report can be accessed at https://www.financial-market-news.com/2017/06/18/synthetic-biologics-inc-syn-receives-consensus-rating-of-buy-from-analysts.html.

Institutional investors have recently made changes to their positions in the stock. UBS Group AG boosted its position in shares of Synthetic Biologics by 10.3% in the first quarter. UBS Group AG now owns 214,357 shares of the company’s stock valued at $135,000 after buying an additional 20,038 shares during the last quarter. Bank of New York Mellon Corp increased its stake in shares of Synthetic Biologics by 3.1% in the first quarter. Bank of New York Mellon Corp now owns 263,598 shares of the company’s stock valued at $166,000 after buying an additional 7,962 shares during the period. Geode Capital Management LLC increased its stake in shares of Synthetic Biologics by 2.7% in the first quarter. Geode Capital Management LLC now owns 551,538 shares of the company’s stock valued at $347,000 after buying an additional 14,395 shares during the period. Norges Bank purchased a new stake in shares of Synthetic Biologics during the fourth quarter valued at about $356,000. Finally, State Street Corp increased its stake in shares of Synthetic Biologics by 0.5% in the fourth quarter. State Street Corp now owns 954,323 shares of the company’s stock valued at $727,000 after buying an additional 5,195 shares during the period.

Synthetic Biologics Company Profile

Synthetic Biologics, Inc is a clinical-stage company. The Company is engaged in developing therapeutics to protect the gut microbiome while targeting pathogen-specific diseases. The Company’s lead product candidates in Phase II development are SYN-010, which is intended to reduce the impact of methane-producing organisms in the gut microbiome to treat an underlying cause of irritable bowel syndrome with constipation (IBS-C), and SYN-004, which is designed to protect the gut microbiome (gastrointestinal (GI) microflora) from the effects of certain commonly used intravenous (IV) antibiotics for the prevention of C.

Receive News & Ratings for Synthetic Biologics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Synthetic Biologics Inc and related companies with MarketBeat.com's FREE daily email newsletter.